Recombinant Vaccines Market
Global Recombinant Vaccine Market Size, Share & Trends Report by Type (Sunbit Vaccine and Live Attenuated Vaccine), By Route of Administration (Oral and Parenteral), by Disease (Human Papilloma Virus, Hepatitis b, Rotavirus, and Others), and by Distribution channel (Hospitals and Retail Pharmacies and Government Suppliers) Forecast (2022-2028)
The global recombinant vaccine market is anticipated to grow at a CAGR of 3.36% during the forecast period. A recombinant vaccine is a vaccine produced through recombinant DNA technology. The rise in the prevalence of non-communicable diseases is expected to accelerate the growth of the market during the forecast period. For instance, according to the data published by World Health Organization in April 2021, non-communicable diseases kill 41 million people each year, which is equivalent to 71% of mortalities globally. Further, every year more than 15 million people between the age group of 30 -69 die from non-communicable diseases. Moreover, chronic health issues can impair ones’ ability to defend against infection, thus recombinant vaccine plays a major role in stimulating the immune response, which further adds to the growth of the market during the forecast period.
Impact of COVID-19 Pandemic on Global Recombinant Vaccine Market
COVID-19 has positively impacted the global recombinant vaccine market. The need for a vaccine to defend against COVID-19 has led to major investments in vaccine developments for purpose of emergency use. For instance, in January 2022, the WHO Strategic Advisory Group of Experts on immunization (SAGE) has issued recommendations for use of the Oxford/AstraZeneca COVID-19 vaccine for emergency use. Also, the COVID-19 pandemic had a minimal impact on the supply chain, as the movement of essential medicines and vaccines was given major preference. Thus, the need for immunization has positively impacted the global recombinant vaccine market.
Segmental Outlook
The global recombinant vaccine is segmented based on type, route of administration, diseases, and distribution channel. Based on type the market is sub-segmented into subunit vaccines and live attenuated vaccines. Based on by route of administration the market is sub-segmented into oral and parenteral. Based on disease, the market is further sub-segmented into hepatitis B, human papillomavirus Rotavirus, and others. Based on the distribution channel, the market is sub-segmented into hospital and retail pharmacies and government suppliers. Among these, the government supplier segment is anticipated to propel the growth of the market owing to the continuous distribution of vaccines across the globe.?
Global Recombinant Vaccine Market Share by Disease,2021 (%)
Rotavirus Segment is Anticipated to Hold a Prominent Share in the Global Recombinant Vaccine Market
The rise in the prevalence of diarrhea among infants is expected to drive the market during the forecast period. For instance, in October 2021, the National Family Health Survey estimated that the prevalence of childhood diarrhea has increased from 9 % in 2016 to 9.2% in 2020. Also, in 2019, according to WHO, Diarrhoeal disease is the second leading cause of death in children under five years old and was accountable for the deaths of 3,70,000 children in 2019. Moreover, bacterial infections are one of the factors for diarrhea-associated deaths. Therefore, the need for a vaccine is anticipated as an important factor in preventing diarrhea-associated deaths. Furthermore, an increase in the prevalence of rotavirus is anticipated to rise the demand for recombinant vaccines.
Regional Outlook
The global recombinant vaccine market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement. Among these, the Asia-pacific region is expected to hold a considerable share in the market over the forecast period owing to a rise in initiatives in vaccine development. ?
Global Recombinant Vaccine Market, by Region 2022-2028
The North American Region is Estimated to Hold Major Share in Global Recombinant Vaccine Market.
The North American region is anticipated to hold a prominent share in the market during the forecast period owing to the continuous R&D in vaccine development. For instance, in August 2021, Pfizer and BioNTech have received approval from the food and drug Administration to market the vaccines to individuals aged 16 and above under the market name CORMINATY. Also, in July 2020, Moderna announced its phase 3 study of a vaccine against COVID-19 and further started its dosing participants in 2020. Thus, continuous R&D are anticipated to accelerate the growth of the global recombinant vaccine market in the region.
Market Players Outlook
The major players serving the global recombinant vaccine market are GlaxoSmithKline, Sanofi, Novartis AG, Merck & Co.Inc, Pfizer Inc, Bharat Biotech, Bayer AG, and more. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in December 2019, Merck & Co.Inc, received a green signal from US Food and Drug Administration (FDA) to launch everbo. Everbo is a recombinant vaccine that protects adults aged 18 years and above against Ebola virus disease, caused by the Zaire Ebola virus.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global recombinant vaccine market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on The Global Recombinant Vaccine Market
- Recovery Scenario of Global Recombinant Vaccine Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Bharat Biotech
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Bayer AG
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. GlaxoSmithKline Plc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Novaritis AG
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Sanofi
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Recombinant Vaccine Market by Type
4.1.1. Sunbit Vaccine
4.1.2. Live Attenuated Vaccine
4.2. Global Recombinant Vaccine Market by Route of Administration
4.2.1. Oral
4.2.2. Parenteral
4.3 Global Recombinant Vaccine Market by Disease
4.3.1 Human Papilloma Virus
4.3.2 Hepatitis –b
4.3.3 Rotavirus
4.4 Global Recombinant Vaccine Market by Distribution Channel
4.4.1 Hospital and Retail Pharmacies
4.4.2 Government Suppliers
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Alnylam Pharmaceuticals, Inc.
6.2. AstraZeneca Plc.
6.3. AmbioPharm, Inc.
6.4. Biocon Ltd.
6.5. Daiichi Sankyo Co.
6.6. Dynavax Technologies
6.7. Dr.Reddys Laboratories, Ltd.
6.8. Ionis Pharmaceuticals, Inc.
6.9. Johnson & Johnson Services, Inc
6.10. Pfizer Inc.
6.11. Serum Insititute of India Pvt.Ltd
6.12. Moderna,Inc.
6.13. Merck & Co.
6.14. Takeda Pharmacuetical Co ,Ltd.
1. GLOBAL RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL SUNBIT VACCINE RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL LIVE ATTENUATED ANTI-BASED-BODY TREATMENT IN RECOMBINANT VACCINE
4. GLOBAL RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
5. GLOBAL ORAL IN RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL PARENTERAL IN RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE
8. GLOBAL HUMAN PAPILLOMA VIRUS IN RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL HEPATITIS –B IN RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL ROTAVIRUS IN RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
12. GLOBAL HOSPITAL AND RETAIL PHARMACIES IN RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL GOVERNMENT SUPPLIER IN RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. GLOBAL RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
15. NORTH AMERICAN RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. NORTH AMERICAN RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
17. NORTH AMERICAN RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
18. NORTH AMERICAN RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
19. NORTH AMERICAN RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
20. EUROPEAN RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. EUROPEAN RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
22. EUROPEAN RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
23. EUROPEAN RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
24. EUROPEAN RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL 2021-2028 ($ MILLION)
25. ASIA-PACIFIC RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
26. ASIA-PACIFIC RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE 2021-2028 ($ MILLION)
27. ASIA-PACIFIC RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
28. ASIA-PACIFIC RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE 2021-2028 ($ MILLION)
29. ASIA-PACIFIC RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
30. REST OF THE WORLD RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
31. REST OF THE WORLD RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
32. REST OF THE WORLD RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
33. REST OF THE WORLD RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
34. REST OF THE WORLD RECOMBINANT VACCINE MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL , 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL RECOMBINANT VACCINE MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL RECOMBINANT VACCINE MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL RECOMBINANT VACCINE MARKET, 2021-2028 (%)
4. GLOBAL RECOMBINANT VACCINE MARKET SHARE BY TYPE, 2021VS 2028 (%)
5. GLOBAL SUBUNIT VACCINE IN RECOMBINANT VACCINE MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
6. GLOBAL LIVE ATTENUATED ANTI-BASED-BODY TREATMENT IN RECOMBINANT VACCINE MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
7. GLOBAL RECOMBINANT VACCINE MARKET SHARE BY ROUTE OF ADMINISTRATION, 2021VS 2028 (%)
8. GLOBAL ORAL RECOMBINANT VACCINE MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
9. GLOBAL PARENTERAL IN RECOMBINANT VACCINE MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
10. GLOBAL RECOMBINANT VACCINE MARKET SHARE BY DISEASE, 2021VS 2028 (%)
11. GLOBAL HUMAN PAPILLOMAVIRUS ANTI-BASED-BODY TREATMENT IN RECOMBINANT VACCINE MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
12. GLOBAL HEPATITIS-B ANTI-BASED-BODY TREATMENT IN RECOMBINANT VACCINE MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
13. GLOBAL ROTAVIRUS ANTI-BASED-BODY TREATMENT IN RECOMBINANT VACCINE MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
14. US RECOMBINANT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
15. CANADA RECOMBINANT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
16. UK RECOMBINANT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
17. FRANCE RECOMBINANT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
18. GERMANY RECOMBINANT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
19. ITALY RECOMBINANT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
20. SPAIN RECOMBINANT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
21. REST OF EUROPE RECOMBINANT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
22. INDIA RECOMBINANT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
23. CHINA RECOMBINANT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
24. JAPAN RECOMBINANT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
25. SOUTH KOREA RECOMBINANT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF ASIA-PACIFIC RECOMBINANT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF THE WORLD RECOMBINANT VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
